Establishment Labs Receives U.S. FDA Approval for Motiva Implants

Go back to Establishment Labs Receives U.S. FDA Approval for Motiva Implants

BTIG Reiterates Buy Rating on Establishment Labs Inc. (ESTA)

September 27, 2024 6:12 AM EDT

BTIG analyst Marie Thibault reiterated a Buy rating and $62.00 price target on Establishment Labs Inc. (NASDAQ: ESTA).

The analyst comments "Today after the close, Establishment Labs announced that the FDA approved the Motiva Ergonomix and Round breast implants for primary and revision breast augmentation. This marks the first new breast implant PMA approval since 2013.... More